Bill

Bill > A06927


NY A06927

NY A06927
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.


summary

Introduced
03/18/2025
In Committee
01/07/2026
Crossed Over
Passed
Dead
06/05/2026

Introduced Session

2025-2026 General Assembly

Bill Summary

AN ACT to amend the education law and the public health law, in relation to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria

AI Summary

This bill allows for prescription labels for certain medications, including gonadotropin-releasing hormone agonists (drugs that can suppress puberty), pubertal suppressants (medications to delay puberty), anabolic steroids, alpha reductase inhibitors (drugs often used for prostate issues or hair loss), progestins (a type of hormone), and hormone replacement therapy drugs used to treat gender dysphoria, to display the name or address of the dispensing healthcare practice instead of the individual prescriber, provided the prescriber requests this change and informs the patient.

Committee Categories

Education

Sponsors (21)

Last Action

print number 6927a (on 05/28/2026)

Bill Topics

Civil Rights, Minority Issues, and Civil Liberties
  • ‐ Gender, Identity and Sexual Orientation Discrimination
Health
  • ‐ Regulation of Drug Industry and Pharmacies

bill text


bill summary

Loading...

bill summary

Loading...
Loading...